Karachi: AGP Limited, a prominent entity in the pharmaceutical sector, disclosed its financial results for the nine months and quarter ending September 30, 2025. The Board of Directors, during their meeting on October 24, 2025, decided to forgo any cash dividends, bonus shares, or right shares for this period.
The company's financial performance shows a marked improvement compared to the previous year. Total revenues for the nine months reached 20.34 billion rupees, up from 17.65 billion rupees in the same period last year, signaling a very large move. Gross profit increased to 12.09 billion rupees from 9.81 billion rupees, highlighting the company's robust operational efficiency.
Net profit for the nine-month period surged to 2.85 billion rupees from 1.59 billion rupees, representing a very large move. This profit is attributed to the equity holders of the Holding Company at 2.50 billion rupees, while the non-controlling interest was recorded at 356.22 million rupees. The earnings per share for the nine-month period were reported at 8.92 rupees, an increase from 5.26 rupees the previous year.
According to information available from the Pakistan Stock Exchange (PSX), the company's balance sheet reflects an increase in total assets to 32.07 billion rupees from 29.35 billion rupees at the end of the previous year. Non-current assets rose to 22.99 billion rupees, while current assets totaled 9.09 billion rupees. Shareholders' equity increased to 15.64 billion rupees from 14.57 billion rupees, driven by the substantial profit generation and accumulated reserves.
On the liabilities side, non-current liabilities decreased to 6.57 billion rupees from 7.86 billion rupees, indicating effective management of financial obligations. Current liabilities, however, saw an increase to 9.86 billion rupees from 6.93 billion rupees, mainly due to higher trade and other payables, taxation, and short-term borrowings.
AGP Limited's cash flow from operating activities was positive, generating 3.85 billion rupees, an increase from 2.85 billion rupees the previous year. However, the company experienced a net cash outflow in investing and financing activities, resulting in a decrease in cash and cash equivalents by 1.49 billion rupees during the period.
The company's commitment to enhancing shareholder value is reflected in its strategic allocation of resources, despite the absence of dividend announcements for the current reporting period. AGP Limited continues to focus on optimizing its financial structure, reducing long-term liabilities, and capitalizing on growth opportunities in the pharmaceutical market.